Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J. Uriach & Cia SA

Division of Grupo Uriach
www.uriach.com

Latest From AccuMed International Inc.

Ampersand Medical's Financing Twist

If Ampersand Medical Corp. started with an unusual financing strategy, its current efforts to get listed on a major stock exchange are also a bit innovative and circuitous. The fact that it has managed to survive and progress in a tough era for diagnostics, even though it is a late entrant into the crowded field of cervical cancer screening, is a testament to the value of this approach. Its founder, Peter Gombrich, has started several device and diagnostic companies which have acquired each other or licensed from one another, including AccuMed International and InPath. Now, Ampersand wants to buy AccuMed to gain access to short-term revenues, patents, and technologies related to early-stage cancer detection.
Medical Device Strategy

Optical Detection: From Physicists to Physicians

Several companies formed in the 1990's are poised to validate the clinical potential of light-based diagnostics as they guide through clinical trials products for a wide variety of applications in cancer, dermatology, gastrointestinal and cardiovascular diseases. Developers of the new optical imaging technologies ultimately hope to improve the way physicians diagnose diseases, by enabling insight into conditions where detection is currently inadequate. They hope to improve outcomes by detecting diseases at earlier stages, before pathological changes become visible. Finally, they aim to develop non-invasive systems that offer rapid diagnosis at the point of care, so that physicians can see and treat patients in a single visit. For now, though, companies are approaching the market cautiously. Most have a strategy of getting their products approved for adjunctive applications rather than attempting to win approval for the devices as standalone diagnostic systems that replace current screening methods.
Medical Device Platform Technologies

Ampersand Medical Corp.

Coming in late to the highly competitive and crowded market for cervical cancer screening, Ampersand Medical is doing something completely different. To remove the subjectivity from interpretation of test restuls, it is developing InPath, a comprehensive screening system that uses a cocktail of protein-based biomolecular markers to identify cellular abnormalities associated with cancers at different stages.
Medical Device Platform Technologies

Selected Start-Ups Founded in 2000 (1/00)

{In Vivo} summarizes the technologies of several medical companies founded within the last year. [Camitro Corp.] is developing computational models to predict ADME/PK properties of drug candidates. Researchers will be able to search for and purchase chemical compounds through [ChemNavigator.com]. Launched in September 1999, [Imetrx Inc.] is a cardiovascular interventional device company focused on locating and characterizing unstable coronary plaques that are responsible for atherosclerosis and acute cardiovascular events. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [Protein Pathways Inc.] aims to improve the speed and focus of drug development by determining functions for all genome-encoded proteins. [Trek Diagnostics Systems Inc.], a microbiology diagnostics testing company, was founded in January 1999 with the acquisition of the AccuMed International Inc.'s microbiology division.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Alias(es)
  • J. Uriach & Cia. SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • Grupo Uriach
  • Senior Management
  • Enrique Uriach Tonello, Pres. & CEO
  • Contact Info
  • J. Uriach & Cia SA
    Phone: (34) 93 8649692
    Avinguda Camí Reial, 51-57
    Barcelona, 08184
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register